CONMED Ownership
| CNMD Stock | USD 62.74 0.77 1.24% |
Shares in Circulation | First Issued 1986-03-31 | Previous Quarter 31.1 M | Current Value 31.1 M | Avarage Shares Outstanding 23.9 M | Quarterly Volatility 7.5 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
CONMED |
CONMED Stock Ownership Analysis
About 99.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 1.99. Some equities with similar Price to Book (P/B) outperform the market in the long run. CONMED has Price/Earnings (P/E) ratio of 188.03. The entity last dividend was issued on the 20th of December 2024. The firm had 3:2 split on the 10th of September 2001. CONMED Corporation, a medical technology company, develops, manufactures, and sells surgical devices and related equipment for surgical procedures worldwide. CONMED Corporation was incorporated in 1970 and is headquartered in Largo, Florida. C O operates under Medical Devices classification in the United States and is traded on New York Stock Exchange. It employs 3800 people. For more info on CONMED please contact Curt Hartman at 727 392 6464 or go to https://www.conmed.com.Besides selling stocks to institutional investors, CONMED also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different CONMED's stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align CONMED's strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
CONMED Quarterly Liabilities And Stockholders Equity |
|
CONMED Insider Trades History
Only 1.44% of CONMED are currently held by insiders. Unlike CONMED's institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against CONMED's private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of CONMED's insider trades
CONMED Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as CONMED is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading CONMED backward and forwards among themselves. CONMED's institutional investor refers to the entity that pools money to purchase CONMED's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Fuller & Thaler Asset Management Inc | 2024-12-31 | 862.7 K | Jpmorgan Chase & Co | 2024-09-30 | 849.5 K | Dimensional Fund Advisors, Inc. | 2024-12-31 | 775.4 K | Geode Capital Management, Llc | 2024-12-31 | 692.8 K | Cooke & Bieler Lp | 2024-12-31 | 664 K | Principal Financial Group Inc | 2024-12-31 | 625.1 K | Deerfield Management Co | 2024-12-31 | 612 K | Clearbridge Advisors, Llc | 2024-12-31 | 543 K | Arrowmark Colorado Holdings, Llc (arrowmark Partners) | 2024-12-31 | 494.9 K | Blackrock Inc | 2024-12-31 | 4.9 M | Vanguard Group Inc | 2024-12-31 | 3.6 M |
CONMED Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific CONMED insiders, such as employees or executives, is commonly permitted as long as it does not rely on CONMED's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases CONMED insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
CONMED Outstanding Bonds
CONMED issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. CONMED uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most CONMED bonds can be classified according to their maturity, which is the date when CONMED has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
CONMED Corporate Filings
8K | 25th of February 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
10K | 18th of February 2025 Annual report required by the U.S. Securities and Exchange Commission (SEC) of a company financial performance | ViewVerify |
F4 | 13th of February 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
F3 | 31st of January 2025 The report used by insiders such as officers, directors, and major shareholders (beneficial owners holding more than 10% of any class of the company's equity securities) to declare their ownership of a company's stock | ViewVerify |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether CONMED is a strong investment it is important to analyze CONMED's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact CONMED's future performance. For an informed investment choice regarding CONMED Stock, refer to the following important reports:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in CONMED. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. For information on how to trade CONMED Stock refer to our How to Trade CONMED Stock guide.You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of CONMED. If investors know CONMED will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about CONMED listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.028 | Dividend Share 0.8 | Earnings Share 4.25 | Revenue Per Share | Quarterly Revenue Growth 0.058 |
The market value of CONMED is measured differently than its book value, which is the value of CONMED that is recorded on the company's balance sheet. Investors also form their own opinion of CONMED's value that differs from its market value or its book value, called intrinsic value, which is CONMED's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because CONMED's market value can be influenced by many factors that don't directly affect CONMED's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between CONMED's value and its price as these two are different measures arrived at by different means. Investors typically determine if CONMED is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, CONMED's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.